China’s medtech shake-up forces rethink on pricing, IP and innovation

A report warns that procurement reforms in Mainland China, alongside the rise of open robotics platforms, supply chain disruption and GLP-1 drugs, are challenging existing medtech business models.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com

More on this story

MedTech

Abbott fends off Chinese rival’s patent challenge at UPC

18 August 2026 The European court has backed Abbott in a dispute over glucose-monitoring technology, while offering guidance on a key added-matter issue.

MedTech

Invisalign maker secures first China win against clear aligner rival

13 August 2026 Clear aligner rivals are fighting over orthodontic technology across several major markets and the latest development in China has raised the stakes.

MedTech

The UPC plugs another gap in its procedural rulebook

7 August 2026 A new UPC Court of Appeal ruling closes an important procedural gap, with significant implications for how in-house teams structure validity defences, manage litigation costs and prepare for appeals, says Florian Laus of Simmons & Simmons.

More features

Paul, Weiss finds appellate ‘star’ to lead Supreme Court practice

The buyers' wishlist: What makes a life sciences deal stack up?

UK appoints ex-engineer as new intellectual property Minister

Stris & Maher opens new Dallas office with partner hires

Teva and Aurinia settle generics dispute over lupus drug, voclosporin

10x Genomics dealt major blow in sequencing fight

SK Biopharmaceuticals settles epilepsy generic dispute

Vanda revives challenge over braille-free label on generic sleep disorder drug

China’s medtech shake-up forces rethink on pricing, IP and innovation

More on this story

Editor's picks

Editor's picks

More features